Study design
Tumour, rectal cancer, CRC
COLORECTAL CANCER, TUMOUR, RECTAL CANCER, RELAPSE
TRACC Part C is a multi-centre, prospective, randomised study of patients with resected high risk stage II and stage III CRC who have undergone curative surgery with an R0 resection designed to demonstrate non-inferiority of ctDNA guided ACT versus SOC chemotherapy. Patients with rectal cancer who have undergone neo-adjuvant radiotherapy with or without concurrent chemotherapy (but not TNT) are also eligible. A list of participating sites is available at Tracking Mutations in Cell Free Tumour DNA to Predict Relapse in Early Colorectal Cancer—Full Text View—ClinicalTrials.gov. Eligible patients are randomly assigned to receive either ctDNA guided ACT (intervention; Arm A) or SOC chemotherapy (comparator; Arm B) (Fig. Study schema for TRACC Part C